PRF Technologies (PRFX) Income from Continuing Operations (2020 - 2024)
PRF Technologies (PRFX) recorded quarterly Income from Continuing Operations of 7345000.0 in Q2 2024, down 31.99% on a QoQ basis from 5565000.0 in Q1 2024, and down 236.77% year-over-year from 5370246.4 in Q3 2023.
PRF Technologies (PRFX) Income from Continuing Operations (2020 - 2024) Analysis & Trends
PRF Technologies has disclosed Income from Continuing Operations across 5 years of filings, most recently posting 7345000.0 for Q2 2024.
- Quarterly Income from Continuing Operations fell 236.77% year-over-year to 7345000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was 17771000.0 (down 80.2% YoY) and the FY2025 annual result came in at 5022000.0, up 65.57% from the prior year.
- Income from Continuing Operations fell to 7345000.0 in Q2 2024, from 5565000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 132000.0 in Q1 2020 and troughed at 7345000.0 in Q2 2024.
- A 5-year average of 2223833.33 and a median of 1806500.0 in 2021 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations slumped 1444.7% — and 2023, when it jumped 38.12%.
- Tracing PRFX's Income from Continuing Operations over 5 years: stood at 691000.0 in 2020, then slumped by 151.95% to 1741000.0 in 2021, then plunged by 87.02% to 3256000.0 in 2022, then dropped by 9.46% to 3564000.0 in 2023, then tumbled by 106.09% to 7345000.0 in 2024.
- Business Quant data shows PRFX's Income from Continuing Operations at 7345000.0 in Q2 2024, 5565000.0 in Q1 2024, and 3564000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | PRF Technologies | 933,081.16 | -2.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -7.35 Mn |
| Mar 31, 2024 | -5.57 Mn |
| Dec 31, 2023 | -3.56 Mn |
| Sep 30, 2023 | -1.30 Mn |
| Jun 30, 2023 | -2.18 Mn |
| Mar 31, 2023 | -2.33 Mn |
| Dec 31, 2022 | -3.26 Mn |
| Sep 30, 2022 | -2.10 Mn |
| Jun 30, 2022 | -1.85 Mn |
| Mar 31, 2022 | -1.67 Mn |
| Dec 31, 2021 | -1.74 Mn |
| Sep 30, 2021 | -1.77 Mn |
| Jun 30, 2021 | -1.66 Mn |
| Mar 31, 2021 | -2.04 Mn |
| Dec 31, 2020 | -691,000.00 |
| Sep 30, 2020 | -700,000.00 |
| Jun 30, 2020 | -148,000.00 |
| Mar 31, 2020 | -132,000.00 |